定坤丹治疗慢性阻塞性肺疾病稳定期气滞血瘀型患者评价

Effect of Dingkundan in Treatment of Qi Stagnation and Blood Stasis Syndrome in Patients with Chronic Obstructive Pulmonary Disease at Stable Phase

目的:探讨定坤丹治疗慢性阻塞性肺疾病稳定期气滞血瘀型患者疗效的研究。方法:采用随机对照的临床设计方法,将2019年6月至2019年12月就诊于中国中医科学院广安门医院呼吸科门诊及住院部诊断为COPD稳定期气滞血瘀证的60例患者按照1∶1分为观察组和对照组。研究期间,两组无脱落、失访或剔除情况发生。在两组均采用中医肺康复训练的基础上,观察组口服定坤丹7 g/次,每日2次;对照组口服同样规格的定坤丹淀粉模拟剂7 g/次,每日2次。两组疗程均为12周。进行治疗前后患者自我评估测试量表(CAT)、改良的英国医学研究委员会呼吸困难量表(mMRC)、疲劳量表-14(FS-14)、焦虑自评量表(SAS)、抑郁自评量表(SDS)量表、6 min步行距离(6MWD)和肺功能各项指标评价。结果:与本组治疗前比较,两组患者治疗后CAT、mMRC、FS-14、SAS评分和6MWD均有,明显改善(P<0.05),观察组SDS评分及肺功能各项指标有明显改善(P<0.05)。与对照组治疗后比较,观察组患者CAT、FS-14、SAS、SDS评分和6MWD改善更加明显(P<0.05)。结论:定坤丹治疗慢性阻塞性肺疾病稳定期气滞血瘀型患者具有明确疗效,可以减轻症状负担、提升运动能力、改善心理状况,并具有改善肺功能的潜在可能。

Objective:To explore the effect of Dingkundan on Qi stagnation and blood stasis syndrome in patients with chronic obstructive pulmonary disease(COPD)at a stable phase.Method:A randomized controlled clinical design method was adopted,and 60 patients who were diagnosed with Qi stagnation and blood stasis syndrome in COPD at a stable phase in the outpatient and inpatient departments of the respiratory department of Guang'anmen Hospital of China Academy of Chinese Medical Sciences from June 2019 to December 2019 were divided into observation group and control group according to 1∶1.During the study period,there was no dropout,loss of follow-up,or exclusion between the two groups.On the basis of both groups receiving traditional Chinese medicine(TCM)lung rehabilitation training,the observation group took Dingkundan 7 g/time orally,twice a day.The control group received oral administration of the same specification of Dingkundan starch simulator of 7 g/time,twice a day.Both groups have a treatment period of 12 weeks.The COPD Assessment Test(CAT),modified Medical Research Council(mMRC),fatigue scale-14(FS-14),self-rating anxiety scale(SAS),self-rating depression scale(SDS),6-minute walk distance(6MWD),and pulmonary function before and after treatment were evaluated.Result:After treatment,both groups showed improvements in CAT,mMRC,FS-14,SAS scores,and 6MWD(P<0.05).The observation group also showed improvements in SDS scores and lung function indicators(P<0.05).Compared with the control group after treatment,the observation group showed more significant improvement in CAT,FS-14,SAS,SDS scores,and 6MWD(P<0.05).Conclusion:Dingkundan has a clear therapeutic effect on Qi stagnation and blood stasis syndrome in patients with COPD at a stable phase.It can reduce symptom burden,enhance exercise capacity,and improve psychological status and has the potential to improve lung function.